Payment overview · 2025
General Payments
$2,024.33
57 reported records · 21 companies
Healthcare provider profile · identity verified
Leonard Eugene Ellison, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTHFIELD, MI · NPI 1679575328
Verified facts
What the public records show
CMS Open Payments records show Leonard Eugene Ellison, MD received $2,024.33 in general payments during 2025 across 57 reported records.
JAZZ PHARMACEUTICALS INC. accounted for 25.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 565 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Gemtesa by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $519.26 | 25.6% | 8 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $359.28 | 17.8% | 9 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $212.29 | 10.5% | 10 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $135.78 | 6.7% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $129.17 | 6.4% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $117.08 | 5.8% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $112.00 | 5.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $71.51 | 3.5% | 3 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$63.08 | 3.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.48 | 2.6% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $33.95 | 1.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.45 | 1.6% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $27.82 | 1.4% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.59 | 1.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.16 | 1.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.00 | 1.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $19.50 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.06 | 0.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.98 | 0.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.50 | 0.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.39 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,827.85 | 55 |
| Education | $196.48 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $519.26 | 8 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $247.79 | 8 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $212.29 | 10 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $129.17 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $129.17 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $117.08 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $71.51 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $63.08 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.48 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $50.79 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $33.95 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.91 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.45 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.16 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 119 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 33 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
565 | 75 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1206 | 226 |
| Amlodipine Besylate | Amlodipine Besylate | 1156 | 195 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 782 | 131 |
| Eliquis | Apixaban | 565 | 75 |
| Furosemide | Furosemide | 539 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 520 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 510 | 94 |
| Carvedilol | Carvedilol | 509 | 89 |
| Losartan Potassium | Losartan Potassium | 502 | 97 |
| Lisinopril | Lisinopril | 487 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 453 | 84 |
| Metformin Hcl | Metformin Hcl | 439 | 64 |
| Gabapentin | Gabapentin | 425 | 79 |
| Clopidogrel | Clopidogrel Bisulfate | 362 | 56 |
| Potassium Chloride | Potassium Chloride | 361 | 78 |
| Hydralazine Hcl | Hydralazine Hcl | 347 | 68 |
| Omeprazole | Omeprazole | 339 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 334 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 323 | 77 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 320 | 47 |
| Nifedipine Er | Nifedipine | 313 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 302 | 52 |
| Levetiracetam | Levetiracetam | 301 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 269 | 45 |
| Famotidine | Famotidine | 261 | 54 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 260 | 58 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 239 | 38 |
| Pregabalin | Pregabalin | 221 | 42 |
| Mirtazapine | Mirtazapine | 186 | 44 |
| Trazodone Hcl | Trazodone Hcl | 185 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 182 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 181 | 40 |
| Ibuprofen | Ibuprofen | 177 | 44 |
| Alprazolam | Alprazolam | 175 | 29 |
| Xarelto | Rivaroxaban | 167 | 19 |
| Clonidine Hcl | Clonidine Hcl | 162 | 32 |
| Simvastatin | Simvastatin | 147 | 29 |
| Meloxicam | Meloxicam | 146 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 142 | 36 |
| Sertraline Hcl | Sertraline Hcl | 140 | 24 |
| Entresto | Sacubitril/Valsartan | 137 | 20 |
| Donepezil Hcl | Donepezil Hcl | 136 | 32 |
| Spironolactone | Spironolactone | 136 | 29 |
| Methocarbamol | Methocarbamol | 128 | 41 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 126 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 125 | 31 |
| Baclofen | Baclofen | 121 | 22 |
| Finasteride | Finasteride | 119 | 17 |
| Jardiance | Empagliflozin | 119 | 33 |
| Varenicline Tartrate | Varenicline Tartrate | 117 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 115 | 20 |
| Januvia | Sitagliptin Phosphate | 115 | 15 |
| Allopurinol | Allopurinol | 113 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 32 |
| Ventolin Hfa | Albuterol Sulfate | 107 | 29 |
| Bumetanide | Bumetanide | 102 | 15 |
| Farxiga | Dapagliflozin Propanediol | 102 | 12 |
| Memantine Hcl | Memantine Hcl | 97 | 14 |
| Ozempic | Semaglutide | 97 | 14 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 93 | 26 |
| Prednisone | Prednisone | 91 | 27 |
| Ondansetron Odt | Ondansetron | 87 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 15 |
| Montelukast Sodium | Montelukast Sodium | 86 | 18 |
| Latanoprost | Latanoprost | 85 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 85 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 80 | 14 |
| Chlorthalidone | Chlorthalidone | 78 | 12 |
| Divalproex Sodium | Divalproex Sodium | 75 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 73 | 20 |
| Olanzapine | Olanzapine | 73 | 17 |
| Risperidone | Risperidone | 73 | 12 |
| Novolog Flexpen | Insulin Aspart | 72 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 12 |
| Glipizide | Glipizide | 67 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | suppressed |
| Naproxen | Naproxen | 65 | 17 |
| Sucralfate | Sucralfate | 64 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 63 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 15 |
| Lactulose | Lactulose | 59 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 56 | 18 |
| Myrbetriq | Mirabegron | 56 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 54 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 19 |
| Enalapril Maleate | Enalapril Maleate | 48 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 48 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 46 | 19 |
| Atenolol | Atenolol | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 42 | 17 |
| Midodrine Hcl | Midodrine Hcl | 41 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Fluconazole | Fluconazole | 39 | 15 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 38 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 37 | 23 |
| Klor-Con M20 | Potassium Chloride | 36 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 34 | 11 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | 12 |
| Metolazone | Metolazone | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Gemtesa | Vibegron | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 12 |
| Brimonidine Tartrate | Brimonidine Tartrate | 32 | suppressed |
| Clonidine | Clonidine | 32 | suppressed |
| Haloperidol | Haloperidol | 32 | suppressed |
| Lidocaine | Lidocaine | 32 | 13 |
| Diazepam | Diazepam | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Methadone Hcl | Methadone Hcl | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 26 |
| Santyl | Collagenase Clostridium Hist. | 31 | 20 |
| Cephalexin | Cephalexin | 30 | 22 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 29 | suppressed |
| Enulose | Lactulose | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | suppressed |
| Nystatin | Nystatin | 27 | 15 |
| Azithromycin | Azithromycin | 26 | 21 |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Novolog | Insulin Aspart | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 17 |
| Nitroglycerin | Nitroglycerin | 25 | 11 |
| Nyamyc | Nystatin | 25 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 24 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 20 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Brilinta | Ticagrelor | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | 15 |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 20 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Calcium Acetate | Calcium Acetate | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Austedo | Deutetrabenazine | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | 15 |
| Folic Acid | Folic Acid | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Dronabinol | Dronabinol | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,024.33 · 57 records | JAZZ PHARMACEUTICALS INC. | AUSTEDO XR, BREZTRI, CREXONT, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, EPIDIOLEX, FREESTYLE LIBRE 3, Fintepla, GEMTESA, JARDIANCE, LifeVest, MOUNJARO, PAXLOVID, TRELEGY ELLIPTA, ULTOMIRIS, VALTOCO, VRAYLAR, Veozah, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error